Kiniksa Pharmaceuticals International (KNSA) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kiniksa Pharmaceuticals International is the larger company by market cap ($6.14 billion vs $5.29 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | MANE |
|---|---|---|
| Share price | $78.75 | $126.63 |
| Market cap | $6.14B | $5.29B |
| 1-day change | +1.01% | +14.13% |
| YTD return | +90.91% | — |
| 1-year return | +105.56% | — |
| 5-year return | +587.77% | — |
| P/E ratio (TTM) | 79.55 | — |
| Forward P/E | 48.69 | — |
| EPS (TTM) | $0.99 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $677.56M | — |
| Revenue growth (YoY) | +60.09% | — |
| Net income (latest FY) | $59.01M | $-70.00M |
| Gross margin | 88.54% | — |
| Operating margin | 11.40% | — |
| Net margin | 8.71% | — |
| 52-week high | $82.94 | $136.72 |
| 52-week low | $35.20 | $32.00 |
| Distance from 52-week high | -5.05% | -7.38% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +24.44% | +29.12% |
| Average volume | 578.96K | 779.41K |
| Shares outstanding | 48.29M | 41.78M |
| Employees | 366 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
KNSA vs MANE FAQ
Which is bigger, Kiniksa Pharmaceuticals International or Veradermics?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $6.14B compared with $5.29B for Veradermics (MANE).
Are Kiniksa Pharmaceuticals International and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.